WallStreetZenWallStreetZen

NASDAQ: DFTX
Definium Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DFTX

Based on 6 analysts offering 12 month price targets for Definium Therapeutics Inc

Min Forecast
$20.00+32.89%
Avg Forecast
$29.83+98.23%
Max Forecast
$61.00+305.32%

Should I buy or sell DFTX stock?

Based on 6 analysts offering ratings for Definium Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 50%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DFTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates DFTX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their DFTX stock forecasts and price targets.

DFTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-23
lockedlocked$00.00+00.00%2025-11-07
lockedlocked$00.00+00.00%2025-11-07
lockedlocked$00.00+00.00%2025-10-13
lockedlocked$00.00+00.00%2025-08-04
Chardan Capital
Top 4%
97
Strong BuyMaintains$20.00+32.89%2025-08-01

1 of 1

Forecast return on equity

Is DFTX forecast to generate an efficient return?

Company
77.86%
Industry
355.62%
Market
208.51%
DFTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DFTX forecast to generate an efficient return on assets?

Company
42.92%
Industry
123.2%
DFTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DFTX earnings per share forecast

What is DFTX's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$1.83
Avg 2 year Forecast
-$1.75
Avg 3 year Forecast
-$1.11

DFTX revenue forecast

What is DFTX's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$45.7M
Avg 3 year Forecast
$136.7M

DFTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DFTX$15.05$29.83+98.23%Strong Buy
NRIX$19.21$30.13+56.82%Strong Buy
INVA$19.44$32.25+65.90%Buy
NTLA$12.50$14.58+16.62%Buy
FTRE$16.50$17.07+3.46%Buy
View Top Biotech Stocks

Definium Therapeutics Stock Forecast FAQ

Is Definium Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: DFTX) stock is to Strong Buy DFTX stock.

Out of 6 analysts, 3 (50%) are recommending DFTX as a Strong Buy, 3 (50%) are recommending DFTX as a Buy, 0 (0%) are recommending DFTX as a Hold, 0 (0%) are recommending DFTX as a Sell, and 0 (0%) are recommending DFTX as a Strong Sell.

If you're new to stock investing, here's how to buy Definium Therapeutics stock.

What is DFTX's earnings growth forecast for 2026-2028?

(NASDAQ: DFTX) Definium Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.49%.

Definium Therapeutics's earnings in 2026 is -$168,098,000.On average, 13 Wall Street analysts forecast DFTX's earnings for 2026 to be -$180,557,657, with the lowest DFTX earnings forecast at -$200,801,314, and the highest DFTX earnings forecast at -$157,220,809. On average, 11 Wall Street analysts forecast DFTX's earnings for 2027 to be -$172,194,220, with the lowest DFTX earnings forecast at -$223,005,306, and the highest DFTX earnings forecast at -$127,224,734.

In 2028, DFTX is forecast to generate -$109,187,685 in earnings, with the lowest earnings forecast at -$197,905,142 and the highest earnings forecast at -$32,064,770.

What is DFTX's revenue growth forecast for 2026-2028?

(NASDAQ: DFTX) Definium Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.

Definium Therapeutics's revenue in 2026 is $0.On average, 12 Wall Street analysts forecast DFTX's revenue for 2026 to be $0, with the lowest DFTX revenue forecast at $0, and the highest DFTX revenue forecast at $0. On average, 11 Wall Street analysts forecast DFTX's revenue for 2027 to be $4,498,820,263, with the lowest DFTX revenue forecast at $0, and the highest DFTX revenue forecast at $19,702,840,893.

In 2028, DFTX is forecast to generate $13,468,188,625 in revenue, with the lowest revenue forecast at $2,332,896,745 and the highest revenue forecast at $29,241,494,378.

What is DFTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: DFTX) forecast ROA is 42.92%, which is lower than the forecast US Biotechnology industry average of 123.2%.

What is DFTX's Price Target?

According to 6 Wall Street analysts that have issued a 1 year DFTX price target, the average DFTX price target is $29.83, with the highest DFTX stock price forecast at $61.00 and the lowest DFTX stock price forecast at $20.00.

On average, Wall Street analysts predict that Definium Therapeutics's share price could reach $29.83 by Dec 23, 2026. The average Definium Therapeutics stock price prediction forecasts a potential upside of 98.23% from the current DFTX share price of $15.05.

What is DFTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: DFTX) Definium Therapeutics's current Earnings Per Share (EPS) is -$1.97. On average, analysts forecast that DFTX's EPS will be -$1.83 for 2026, with the lowest EPS forecast at -$2.04, and the highest EPS forecast at -$1.60. On average, analysts forecast that DFTX's EPS will be -$1.75 for 2027, with the lowest EPS forecast at -$2.26, and the highest EPS forecast at -$1.29. In 2028, DFTX's EPS is forecast to hit -$1.11 (min: -$2.01, max: -$0.33).

What is DFTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: DFTX) forecast ROE is 77.86%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.